What biotx.ai does

biotx.ai is a Berlin/Potsdam-based precision medicine company that operates a genomic causal inference platform applying large-scale Mendelian randomization and colocalization to map how every human gene causally influences diseases and biomarkers across all tissues. The platform ingests a curated catalog of thousands of genome-wide association studies encompassing more than 25 million cases across more than 3,000 diseases, then runs MR analyses on all 23,000 human genes and more than one million omics markers across 60 tissues, generating billions of causal data points. These causally annotated data and AI models trained on them are used to validate drug targets, de-risk clinical programs, and improve clinical trial design by providing genetic causal evidence as a proxy for prospective randomized evidence.

The core technology is a GPU-powered causal AI/ML pipeline running large-scale Mendelian randomization with colocalization, supported by a technology partnership with NVIDIA. biotx.ai has published peer-reviewed work demonstrating that genetic support materially improves Phase 2 clinical trial success rates (the company's stated benchmark is below 30% Phase 2 success without causal validation), and has produced applied studies validating calcium channel blockers for ADHD and targeting SLC13A5 for osteoporosis. The platform is delivered through direct platform licensing and drug discovery co-development partnerships rather than self-serve or marketplace channels.

The company monetizes through platform licensing of causally annotated data and AI models to pharmaceutical and biotechnology customers for target validation and clinical trial design, alongside collaborative drug discovery partnerships (notably with Heartbeat Bio and Kezbio) and a newer customer segment serving venture capital firms for portfolio-level target due diligence. Pricing is not publicly disclosed and is negotiated per partnership. biotx.ai is venture-backed by Hoxton Ventures (lead investor), alongside Oxonian Ventures, Ocama Partners, and Startupbootcamp, and has secured non-dilutive ProFIT grant funding from Investitionsbank des Landes Brandenburg co-funded by the European Regional Development Fund. The company operates from Potsdam, Germany with an 11-person team led by CEO Marco Schmidt and CTO Charles Ravarani.

Name

biotx.ai

Legal name

biotx.ai GmbH

Website

https://biotx.ai

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

biotx.ai applies GPU-powered causal AI and large-scale Mendelian randomization to map how every human gene causally influences diseases across all tissues. The platform serves pharmaceutical, biotechnology, and venture capital customers for drug target validation and clinical trial design.

Ownership category

akta.pro rank

Product category

Genomic Causal Inference Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Genomic causal inference
• Drug target discovery
• Mendelian randomization platform
• Precision medicine analytics
• Causal AI bioinformatics

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Platform Licensing: Licensing of causally annotated data and AI models to pharmaceutical and biotechnology companies for target validation and clinical trial design.
2. Drug Discovery Partnerships: Collaborative drug discovery programs with specialized biotechnology firms and pharmaceutical companies. Leverages platform scale to uncover novel disease biology across multiple therapeutic areas and launch targeted drug discovery programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

biotx.ai operates a unified genomic causal mapping platform that applies large-scale Mendelian randomization and colocalization across thousands of diseases and biomarkers to generate billions of causal data points linking genes to biological outcomes. The platform is licensed to pharmaceutical companies, biotechnology firms, and venture capital investors to validate drug targets, de-risk portfolios, uncover novel therapeutic indications, and improve clinical trial design.

Product overview

biotx.ai operates a unified genomic causal mapping platform that applies large-scale Mendelian randomization and colocalization across thousands of diseases and biomarkers to generate billions of causal data points linking genes to biological outcomes. The platform is offered via direct access (platform licensing) and is used by biotechnology companies, pharmaceutical organizations, and venture capital firms to validate drug targets, identify novel therapeutic targets, uncover new indications for existing programs, and improve clinical trial design. No individually named sub-products, modules, or add-on offerings were identified in the source material — the company's product portfolio appears to be structured as a single integrated platform rather than a modular or multi-product suite.

Differentiator

Problem solved

Functional benefit

Products and services

• Genomic Causal Mapping Platform

Quantifiable outcome

• Phase 2 clinical trial success rates below 30% without causal validation; genetic support significantly improves success rates

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• Heartbeat BiocoreStrategic or Co-development PartnerExisting partnership with Heartbeat Bio for collaborative drug discovery using biotx.ai's causal genomic platform.
• KezbiocoreStrategic or Co-development PartnerExisting partnership with Kezbio for leveraging the causal mapping platform in drug discovery programs.
• NVIDIAcoreTechnology or IntegrationTechnology partnership for GPU-powered computational infrastructure enabling large-scale Mendelian randomization analyses.
• SPRIN-DcoreStrategic or Co-development PartnerSPRIN-D supports the development of the causal drug target identification platform.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Insitro: AI/ML-driven drug discovery platform combining machine learning with high-throughput biology. Comparable to biotx.ai in offering data-driven target identification and partnership-based pharma monetization, though differentiated by Insitro's proprietary lab infrastructure.
• Recursion Pharmaceuticals: AI-enabled drug discovery company using large-scale biological data and ML to identify targets and advance pipelines. Competes with biotx.ai for pharma platform-licensing and partnership dollars in the AI-bio space.
• BenevolentAI: AI platform for drug discovery and target identification, leveraging biomedical knowledge graphs and causal inference. Closely comparable to biotx.ai in applying causal/AI methods to drug target validation and indication expansion.
• Exscientia: AI-native pharma company combining ML-based target identification with molecule design and partnered pipelines. Comparable in business model (platform + partnerships) and customer base (large pharma).
• Owkin: AI-for-drug-discovery company applying ML to multi-omic and clinical data for target discovery and clinical trial optimization. Comparable in serving pharma/biotech with AI-driven evidence and partnership models.
• Standigm: AI-based drug discovery and target identification company with partnered pipelines in pharma. Comparable to biotx.ai in selling platform-driven target discovery services to pharma/biotech.

Emerging players

• Biorelate: AI-driven biomedical knowledge curation and target discovery platform. Comparable to biotx.ai in mining large-scale biomedical evidence to surface novel drug targets, though using NLP rather than Mendelian randomization.
• Causaly: Causal AI platform for life sciences and pharma evidence synthesis. Comparable to biotx.ai in applying causal-inference methods to biomedical questions and in selling into pharma/biotech research workflows.
• Open Targets: Public-private partnership building a target identification platform integrating genetics, omics, and chemistry data. Comparable to biotx.ai in target identification using GWAS/genetics, though operated as a consortium rather than a commercial entity.
• Lantern Pharma: AI-driven precision oncology company using genomic and molecular data to identify and develop targeted therapies. Comparable to biotx.ai in using causal/genomic data for drug development decisions and indication matching.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biotx-ai

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about biotx.ai